Bausch Health Companies Inc at Barclays High Yield Conference Transcript
We have Paul Herendeen, CFO of Bausch; and we have Mark McKenna, President of Salix with us on the podium.
Questions & Answers
I guess, starting off just because we like to start off with all the macro stuff, can you talk about Medicare Part D. There's been a number of proposals that have been pitched out there. Just your thoughts around Medicare Part D, your exposure to Medicare Part D within the various segments, and just your thoughts around what is being proposed?
Yes. Sure. And it's Paul. We are -- first of all, we don't know exactly what's going to happen in terms of changes that we might see and how that will be implemented. Importantly, how it will be implemented. Before I even address the question, I want to be clear because people look at Bausch Health and they think of us kind of as a pharmaceutical company. We are a diversified health care company. And so, when we're talking about Med D and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |